Inmaculada Jiménez‐Nácher

1.4k total citations
27 papers, 992 citations indexed

About

Inmaculada Jiménez‐Nácher is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Inmaculada Jiménez‐Nácher has authored 27 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 14 papers in Virology and 12 papers in Hepatology. Recurrent topics in Inmaculada Jiménez‐Nácher's work include HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (14 papers) and Hepatitis C virus research (12 papers). Inmaculada Jiménez‐Nácher is often cited by papers focused on HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (14 papers) and Hepatitis C virus research (12 papers). Inmaculada Jiménez‐Nácher collaborates with scholars based in Spain, China and United States. Inmaculada Jiménez‐Nácher's co-authors include Vincent Soriano, Daniel González de Requena, Juan González‐Lahoz, Pablo Barreiro, Sonia Rodríguez‐Nóvoa, Marina Núñez, Luz Martı́n-Carbonero, Gema González‐Pardo, Óscar Gallego and Judit Morelló and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Inmaculada Jiménez‐Nácher

27 papers receiving 908 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Inmaculada Jiménez‐Nácher Spain	18	759	461	304	299	185	27	992
Vanitha Sekar United States	19	954 1.3×	537 1.2×	633 2.1×	613 2.1×	195 1.1×	33	1.5k
Stéphanie Dominguez France	16	590 0.8×	370 0.8×	553 1.8×	518 1.7×	141 0.8×	39	1.1k
Simona Landonio Italy	17	615 0.8×	335 0.7×	203 0.7×	107 0.4×	256 1.4×	32	776
Dion F. Coakley United States	18	782 1.0×	536 1.2×	390 1.3×	176 0.6×	174 0.9×	25	1.2k
Hamid Hasson Italy	13	468 0.6×	345 0.7×	224 0.7×	171 0.6×	142 0.8×	69	792
Sabrina Spinosa‐Guzman United States	12	1.2k 1.6×	917 2.0×	207 0.7×	109 0.4×	283 1.5×	20	1.2k
Claudia Martorell United States	14	467 0.6×	217 0.5×	598 2.0×	629 2.1×	155 0.8×	28	1.3k
Marc Antoine Valantin France	9	309 0.4×	217 0.5×	199 0.7×	142 0.5×	162 0.9×	17	579
Frank Tomaka United States	12	653 0.9×	446 1.0×	133 0.4×	80 0.3×	161 0.9×	24	713
Kitty Yale United States	16	1.2k 1.6×	837 1.8×	646 2.1×	230 0.8×	389 2.1×	21	1.9k

Countries citing papers authored by Inmaculada Jiménez‐Nácher

Since Specialization

Citations

This map shows the geographic impact of Inmaculada Jiménez‐Nácher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inmaculada Jiménez‐Nácher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inmaculada Jiménez‐Nácher more than expected).

Fields of papers citing papers by Inmaculada Jiménez‐Nácher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inmaculada Jiménez‐Nácher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inmaculada Jiménez‐Nácher. The network helps show where Inmaculada Jiménez‐Nácher may publish in the future.

Co-authorship network of co-authors of Inmaculada Jiménez‐Nácher

This figure shows the co-authorship network connecting the top 25 collaborators of Inmaculada Jiménez‐Nácher. A scholar is included among the top collaborators of Inmaculada Jiménez‐Nácher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inmaculada Jiménez‐Nácher. Inmaculada Jiménez‐Nácher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiménez‐Nácher, Inmaculada, et al.. (2011). Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opinion on Drug Metabolism & Toxicology. 7(4). 457–477. 31 indexed citations

Morelló, Judit, Lorena Cuenca‐Bermejo, Vincent Soriano, et al.. (2010). Influence of a Single Nucleotide Polymorphism at the Main Ribavirin Transporter Gene on the Rapid Virological Response to Pegylated Interferon–Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection. The Journal of Infectious Diseases. 202(8). 1185–1191. 30 indexed citations

Vispo, Eugenia, Ivana Maida, Francisco J. Blanco, et al.. (2009). Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy. 65(3). 543–547. 40 indexed citations

Medraño, J., Pablo Barreiro, Salvador Resino, et al.. (2009). Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV‐Infected and HIV‐Uninfected Patients. Clinical Infectious Diseases. 49(9). 1397–1401. 30 indexed citations

Rodríguez‐Nóvoa, Sonia, Judit Morelló, Pablo Barreiro, et al.. (2008). Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. AIDS Research and Human Retroviruses. 24(6). 821–825. 31 indexed citations

Mendoza, Carmen de, Inmaculada Jiménez‐Nácher, Carmen Garrido, et al.. (2008). Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. Clinical Infectious Diseases. 46(11). 1782–1785. 16 indexed citations

Rodríguez‐Nóvoa, Sonia, Judit Morelló, Eugenia Vispo, et al.. (2008). Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS. 22(18). 2535–2537. 33 indexed citations

Sánchez‐Conde, Matilde, Rosario Palacios, José Sanz, et al.. (2007). Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. AIDS Research and Human Retroviruses. 23(10). 1237–1241. 8 indexed citations

Rodríguez‐Nóvoa, Sonia, Pilar García‐Gascó, Francisco J. Blanco, et al.. (2007). Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards. AIDS Research and Human Retroviruses. 23(11). 1374–1376. 23 indexed citations

10.

Mendoza, Carmen de, Carmen Garrido, Angélica Corral, et al.. (2007). Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. AIDS Research and Human Retroviruses. 23(7). 879–885. 30 indexed citations

11.

Morelló, Judit, Sonia Rodríguez‐Nóvoa, Inmaculada Jiménez‐Nácher, & Vincent Soriano. (2007). Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. Drug Metabolism Letters. 1(1). 81–84. 8 indexed citations

12.

Rodríguez‐Nóvoa, Sonia, Luz Martı́n-Carbonero, Pablo Barreiro, et al.. (2006). Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 21(1). 41–46. 126 indexed citations

13.

Requena, Daniel González de, Inmaculada Jiménez‐Nácher, & Vincent Soriano. (2005). Short Communication: Changes in Nevirapine Plasma Concentrations Over Time and Its Relationship with Liver Enzyme Elevations. AIDS Research and Human Retroviruses. 21(6). 555–559. 24 indexed citations

14.

Rendón, Ana Lucía, Marina Núñez, Míriam Romero, et al.. (2005). Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(4). 401–405. 61 indexed citations

15.

Requena, Daniel González de, et al.. (2004). Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient. AIDS Research and Human Retroviruses. 20(3). 275–278. 51 indexed citations

16.

Requena, Daniel González de, Óscar Gallego, Angélica Corral, Inmaculada Jiménez‐Nácher, & Vincent Soriano. (2004). Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. AIDS. 18(15). 2091–2094. 12 indexed citations

17.

Requena, Daniel González de, Óscar Gallego, Carmen de Mendoza, et al.. (2003). Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. AIDS Research and Human Retroviruses. 19(6). 457–459. 13 indexed citations

18.

Requena, Daniel González de, Francisco J. Blanco, Teresa García-Benayas, et al.. (2003). Correlation Between Lopinavir Plasma Levels and Lipid Abnormalities in Patients Taking Lopinavir/Ritonavir. AIDS Patient Care and STDs. 17(9). 443–445. 55 indexed citations

19.

Núñez, Marina, Daniel González de Requena, Lucía Gallego, et al.. (2001). Higher Efavirenz Plasma Levels Correlate With Development of Insomnia. JAIDS Journal of Acquired Immune Deficiency Syndromes. 28(4). 399–399. 1 indexed citations

20.

Barreiro, Pablo, Vincent Soriano, E Casas, et al.. (2000). Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS. 14(14). 2153–2157. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact